Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

Also called NCT04270760

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 281 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04270760
  • EudraCT 2019-003688-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Denmark, Iceland, Japan, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04270760. Randomized; double masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2021-12-27 (actual). Results posted on 2023-08-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Condition
Cardiovascular Disease
Intervention (Drug)
Olpasiran
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct04270760
Content hash
e03964024d9fc79e419274cc2fbef653d2a1f6a582aa1556081d15893e8f62a9